儿童导管相关静脉血栓抗凝治疗的安全性与疗效:EINSTEIN-Jr CVC-VTE分析
预设分析显示无复发性静脉血栓(0%;95%CI 0.0%-2.8%),临床相关非大出血发生率为2.4%(95%CI 0.7%-6.5%),均见于利伐沙班组;多数患儿血栓负荷减轻。残余血栓和继续使用中心静脉导管与延长抗凝治疗相关。
要点
- 儿童CVC-VTE抗凝治疗安全有效,无复发性静脉血栓发生。
- 临床相关非大出血发生率为2.4%,均见于利伐沙班组,无大出血。
- 残余血栓和继续使用CVC与延长抗凝治疗相关。
核心结论
- 抗凝治疗在症状性或无症状性儿童CVC-VTE中安全有效,且多数患儿血栓负荷减轻。
主要发现
- 无复发性静脉血栓(0%;95%CI 0.0%-2.8%)。
- 3例发生临床相关非大出血(2.4%;95%CI 0.7%-6.5%),均位于利伐沙班组,无大出血。
- 103例可评估患儿中,57例(55%)完全再通,38例(37%)部分再通。
- 症状性与无症状性CVC-VTE结果相似。
- 61例(48%)患儿在研究期后继续抗凝治疗。
临床怎么用
- 儿童CVC-VTE可考虑抗凝治疗,利伐沙班或标准抗凝均显示安全有效。
- 对于<2岁伴残余血栓或继续使用CVC的患儿,需评估延长抗凝治疗的必要性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anticoagulant treatment of pediatric central venous catheter-related venous thromboembolism (CVC-VTE) has not been specifically evaluated. In EINSTEIN-Jr, 500 children with any VTE received rivaroxaban or standard anticoagulants. A predefined analysis of the CVC-VTE cohort was performed. Children with CVC-VTE (age, birth to 17 years) were administered rivaroxaban or standard anticoagulants during the 1-month (children <2 years) or 3-month (all other children) study period. Predefined outcomes were recurrent VTE, change in thrombotic burden on repeat imaging, and bleeding. Predictors for continuation of anticoagulant therapy beyond the study period were evaluated. One hundred twenty-six children with symptomatic (n = 76, 60%) or asymptomatic (n = 50, 40%) CVC-VTE received either rivaroxaban (n = 90) or standard anticoagulants (n = 36). There was no recurrent VTE (0%; 95% confidence interval [CI], 0.0%-2.8%). Three children had the principal safety outcome: none had major bleeding and 3 children had clinically relevant nonmajor bleeding (2.4%; 95% CI, 0.7%-6.5%), all in the rivaroxaban arm. Complete or partial vein recanalization occurred in 57 (55%) and 38 (37%) of 103 evaluable children, respectively. Results were similar for symptomatic and asymptomatic CVC-VTE. Continuation of anticoagulant therapy beyond the study period occurred in 61 (48%) of children and was associated with residual VTE but only in children <2 years (odds ratio [OR], 20.9; P = .003) and continued CVC use (OR, 6.7; P = .002). Anticoagulant therapy appeared safe and efficacious and was associated with reduced clot burden in most children with symptomatic or asymptomatic CVC-VTE. Residual VTE and continued CVC use were associated with extended anticoagulation. This trial was registered at www.clinicaltrials.gov as #NCT02234843.
引用
- Thom K, Lensing AWA, Nurmeev I, et al. Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE). Blood Adv. 2020. PMID: 33002131. doi:10.1182/bloodadvances.2020002637
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。